We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+21.98%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$679M
AUM Growth
+$8.14M
Cap. Flow
+$879K
Cap. Flow %
0.13%
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$18.7M
2
IFRX icon
InflaRx
IFRX
+$13M
3
VSTM icon
Verastem
VSTM
+$7.91M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$7.58M
5
ELEV
Elevation Oncology
ELEV
+$6.86M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$21.5M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.81M
3
BLUE
bluebird bio
BLUE
+$9.14M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.01M
5
MRNA icon
Moderna
MRNA
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.72%
2 Financials 6.8%
3 Real Estate 0.3%
4 Consumer Discretionary 0.15%
5 Utilities 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
101
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-45,000
Closed -$9.01M
CMA
102
DELISTED
Comerica
CMA
– –
-133,525
Closed -$5.8M
ENTA icon
103
Enanta Pharmaceuticals
ENTA
$400M
– –
-90,000
Closed -$3.64M
IBRX icon
104
ImmunityBio
IBRX
$8.1B
– –
-1,095,795
Closed -$1.99M
ITOS
105
DELISTED
iTeos Therapeutics
ITOS
– –
-216,700
Closed -$2.95M
KRON
106
DELISTED
Kronos Bio
KRON
– –
-200,000
Closed -$292K
NVO
107
Novo Nordisk
NVO
$209B
– –
-270,000
Closed -$21.5M
RCUS icon
108
Arcus Biosciences
RCUS
$3.64B
– –
-147,920
Closed -$2.7M
RVPH
109
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-2,660
Closed -$223K
SCYX icon
110
SCYNEXIS
SCYX
$52M
– –
-47,897
Closed -$1.15M
TIL icon
111
Instil Bio
TIL
$50.3M
– –
-10,000
Closed -$132K
TNXP icon
112
Tonix Pharmaceuticals
TNXP
$192M
– –
-55
Closed -$650K
UMBF icon
113
UMB Financial
UMBF
$11.1B
– –
-20,000
Closed -$1.15M
VNDA icon
114
Vanda Pharmaceuticals
VNDA
$302M
– –
-100,000
Closed -$679K
VINC
115
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-5,088
Closed -$106K
CYT
116
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-100,000
Closed -$182K
ORTX
117
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-50,000
Closed -$269K
SURF
118
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-1,300,000
Closed -$908K
BLU
119
DELISTED
BELLUS Health Inc.
BLU
– –
-300,000
Closed -$2.16M
RXDX
120
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-21,000
Closed -$2.25M
TCRR
121
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-3,399,745
Closed -$5.1M
JNCE
122
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-5,300,087
Closed -$9.81M
FRC
123
DELISTED
First Republic Bank
FRC
– –
-278,759
Closed -$3.9M
BLPH
124
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-893,974
Closed -$7.05M
1 2 3 4
5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tang Capital Management held 124 positions worth $679M, up 1.2% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management's Q2 2023 filing shows 21 new, 25 increased, 15 reduced and 25 closed positions. Its largest new stake was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M. The largest sale was Novo Nordisk, an estimated $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials and Real Estate.

  • Tang Capital Management's largest Q2 2023 buy was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M.
  • Tang Capital Management added most to Atea Pharmaceuticals in Q2 2023, an estimated $7.58M increase.
  • Tang Capital Management's biggest Q2 2023 reduction was bluebird bio, cutting an estimated $9.14M.
  • Tang Capital Management fully exited Novo Nordisk in Q2 2023, selling an estimated $21.5M.
  • Tang Capital Management's ten largest holdings make up 39% of its $679M portfolio in Q2 2023.
  • Tang Capital Management opened 21 new positions and closed 25 in Q2 2023.
  • Tang Capital Management's portfolio value rose 1.2% quarter-over-quarter to $679M.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.